Literature DB >> 15917564

Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus.

Yu C Kim1, Joo H Lee, So H Kim, Myung G Lee.   

Abstract

After intravenous and oral administration of clarithromycin at a dose of 20 mg/kg of body weight to rats with diabetes mellitus induced by alloxan (DMIA) and diabetes mellitus induced by streptozotocin (DMIS), the area under the curve values were significantly smaller than those of respective control rats. The in vitro intrinsic clearance values for the disappearance of clarithromycin were significantly faster in both rats with DMIA and rats with DMIS than in control rats. The above data suggested that metabolism of clarithromycin increased in both types of diabetic rat due to an increase in the expression and mRNA level of CYP3A1(23) in the rats.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15917564      PMCID： PMC1140488          DOI： 10.1128/AAC.49.6.2528-2532.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  30 in total

1.  Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate.

Authors:  Ae K Lee; Joo H Lee; Jong W Kwon; Won B Kim; Sang G Kim; So H Kim; Myung G Lee
Journal:  Biopharm Drug Dispos       Date:  2004-09       Impact factor: 1.627

2.  Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus.

Authors:  J H Park; W I Lee; W H Yoon; Y D Park; J S Lee; M G Lee
Journal:  Biopharm Drug Dispos       Date:  1998-09       Impact factor: 1.627

3.  Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects.

Authors:  F B Eatman; W A Colburn; H G Boxenbaum; H N Posmanter; R E Weinfeld; R Ronfeld; L Weissman; J D Moore; M Gibaldi; S A Kaplan
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

4.  Strain differences in susceptibility of normal and diabetic rats to acetaminophen hepatotoxicity.

Authors:  V F Price; D J Jollow
Journal:  Biochem Pharmacol       Date:  1986-02-15       Impact factor: 5.858

5.  Bile flow decrease and altered bile composition in streptozotocin-treated rats.

Authors:  C E Carnovale; R A Marinelli; E A Rodríguez Garay
Journal:  Biochem Pharmacol       Date:  1986-08-01       Impact factor: 5.858

6.  Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve.

Authors:  W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

7.  New calculation method for mean apparent drug volume of distribution and application to rational dosage regimens.

Authors:  W L Chiou
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

8.  [Changes of CYP2E1 activity in diabetic rat model].

Authors:  L Li; Y Zhang
Journal:  Yao Xue Xue Bao       Date:  1998-12

9.  Pharmacokinetics, blood partition and protein binding of DA-7867, a new oxazolidinone.

Authors:  Soo K Bae; Won-S Chung; Eun J Kim; Jae K Rhee; Jong W Kwon; Won B Kim; Myung G Lee
Journal:  Biopharm Drug Dispos       Date:  2004-04       Impact factor: 1.627

10.  Effects of cysteine on the pharmacokinetics of intravenous clarithromycin in rats with protein-calorie malnutrition.

Authors:  Choong Y Ahn; Eun J Kim; Jong W Kwon; Suk J Chung; Sang G Kim; Chang-K Shim; Myung G Lee
Journal:  Life Sci       Date:  2003-08-22       Impact factor: 5.037
View more
  3 in total

Review 1.  Strategies for preclinical pharmacokinetic investigation in streptozotocin-induced diabetes mellitus (DMIS) and alloxan-induced diabetes mellitus (DMIA) rat models: case studies and perspectives.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-03-06       Impact factor: 2.441

2.  Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes.

Authors:  Dany Patoine; Michaël Petit; Sylvie Pilote; Frédéric Picard; Benoit Drolet; Chantale Simard
Journal:  Pharmacol Res Perspect       Date:  2014-09-01

3.  Comparison of pharmacokinetic parameters of ranolazine between diabetic and non-diabetic rats.

Authors:  Habibeh Mashayekhi-Sardoo; Hossein Kamali; Soghra Mehri; Amirhossein Sahebkar; Mohsen Imenshahidi; Amir Hooshang Mohammadpour
Journal:  Iran J Basic Med Sci       Date:  2022-07       Impact factor: 2.532
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.